HYPOTHESIS: Patients who receive hormone replacement therapy (HRT) and subsequently develop breast cancer are more likely to be diagnosed by palpation than mammography and have a higher stage of cancer at initial diagnosis. DESIGN: Retrospective case series. SETTING: University hospital. PATIENTS: Two hundred ninety-two patients with breast cancer who were postmenopausal. INTERVENTIONS: Clinical examination, mammography, and definitive therapy. MAIN OUTCOME MEASURES: Hormone replacement therapy use, mode of cancer detection, tumor size, nodal status, stage, and survival. RESULTS: Patients receiving HRT prior to diagnosis had significantly more incidences of mammographically detected tumors, ductal carcinoma in situ, T1 lesions, negative nodes, and better survival rates than nonusers. CONCLUSIONS: A history of HRT use had only beneficial and no discernible adverse effects on breast cancer detection and outcomes. These effects of HRT seem to be due to the development of less aggressive tumors rather than earlier detection.
HYPOTHESIS: Patients who receive hormone replacement therapy (HRT) and subsequently develop breast cancer are more likely to be diagnosed by palpation than mammography and have a higher stage of cancer at initial diagnosis. DESIGN: Retrospective case series. SETTING: University hospital. PATIENTS: Two hundred ninety-two patients with breast cancer who were postmenopausal. INTERVENTIONS: Clinical examination, mammography, and definitive therapy. MAIN OUTCOME MEASURES: Hormone replacement therapy use, mode of cancer detection, tumor size, nodal status, stage, and survival. RESULTS:Patients receiving HRT prior to diagnosis had significantly more incidences of mammographically detected tumors, ductal carcinoma in situ, T1 lesions, negative nodes, and better survival rates than nonusers. CONCLUSIONS: A history of HRT use had only beneficial and no discernible adverse effects on breast cancer detection and outcomes. These effects of HRT seem to be due to the development of less aggressive tumors rather than earlier detection.
Authors: Mary Panjari; Robin Bell; Marijana Lijovic; Maria La China; Max Schwarz; Pamela Fradkin; Jo Bradbury; Helen Farrugia; Susan R Davis Journal: Horm Cancer Date: 2010-03-09 Impact factor: 3.869
Authors: Bernard Rosner; Robert J Glynn; A Heather Eliassen; Susan E Hankinson; Rulla M Tamimi; Wendy Y Chen; Michelle D Holmes; Yi Mu; Cheng Peng; Graham A Colditz; Walter C Willett; Shelley S Tworoger Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-08-02 Impact factor: 4.090
Authors: Polly A Newcomb; Kathleen M Egan; Amy Trentham-Dietz; Linda Titus-Ernstoff; John A Baron; John M Hampton; Meir J Stampfer; Walter C Willett Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-04-01 Impact factor: 4.254
Authors: Rainer Fagerholm; Maria Faltinova; Kirsi Aaltonen; Kristiina Aittomäki; Päivi Heikkilä; Mervi Halttunen-Nieminen; Heli Nevanlinna; Carl Blomqvist Journal: Fam Cancer Date: 2018-07 Impact factor: 2.375
Authors: Per Hall; Alexander Ploner; Judith Bjöhle; Fei Huang; Chin-Yo Lin; Edison T Liu; Lance D Miller; Hans Nordgren; Yudi Pawitan; Peter Shaw; Lambert Skoog; Johanna Smeds; Sara Wedrén; John Ohd; Jonas Bergh Journal: BMC Med Date: 2006-06-30 Impact factor: 8.775
Authors: Robert J Biggar; Elisabeth W Andersen; Niels Kroman; Jan Wohlfahrt; Mads Melbye Journal: Breast Cancer Res Date: 2013-02-19 Impact factor: 6.466